|Pre Clinical||Phase 1||Phase 2||Phase 3|
Anthrax Vaccine Candidate
(Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant)
*Phase 3 Study: First subject enrollment targeted for 2018
NuThrax™ (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) is being studied for use as a third generation anthrax vaccine. This candidate consists of BioThrax® (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909.
Active Clinical Trials
Completed Clinical Trials
Seasonal Influenza Therapeutic Candidate
**Phase 2 Study: First subject enrollment targeted for 2017
Zika Therapeutic Candidate
**Phase 1 Study: First subject enrollment targeted for 2017
Burkholderia Therapeutic Candidate
Broad Spectrum Antibiotic
GC-072 is the lead candidate based on Emergent's EV-035 series of broad spectrum antibiotics. These compounds have a novel 4-oxoquinolizine antibacterial backbone showing activity against quinolone-resistant bacterial strains such as Burkholderia pseudomallei.
Pan-filovirus Therapeutic Candidate (Ebola, Marburg, Sudan)
Hyperimmune Platform, Monoclonal Antibody
Clinical Trials Resources
To learn more about Clinical Trials, visit the websites below. These sites are maintained by ClinicalTrials.gov, a web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. ClinicalTrials.gov is maintained by the National Library of Medicine at the National Institutes of Health.